
Opinion|Videos|February 10, 2025
An Academic Perspective to First-Line Treatment Decisions for EGFR-mutated Advanced/Metastatic NSCLC
Author(s)Misako Nagasaka, MD, PhD
The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular profile, comorbidities, and performance status. When discussing options with high-risk patients, healthcare professionals typically take a shared decision-making approach, thoroughly explaining both potential benefits and side effect management strategies. These conversations weigh factors like quality-of-life impact, monitoring requirements, and individual patient preferences to arrive at an optimal treatment strategy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please share the main factors that drive your 1L treatment choice.
- How has your practice adapted in recent years given efficacy/safety from combination therapy?
- How do you discuss combination therapy with your high-risk patients?
- How do you weigh the potential for toxicity vs efficacy/benefits when discussing combination treatment options with your patients?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
3
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
4
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
5

